{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:49:29Z","timestamp":1751374169246,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasitol Res"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00436-021-07266-w","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T06:02:46Z","timestamp":1628488966000},"page":"3307-3317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In vitro evaluation and in vivo efficacy of nitroimidazole-sulfanyl ethyl derivatives against Leishmania (V.) braziliensis and Leishmania (L.) mexicana"],"prefix":"10.1007","volume":"120","author":[{"given":"Zuleima","family":"Blanco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Mijares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hegira","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Fernandez-Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry J.","family":"Oviedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-2361","authenticated-orcid":false,"given":"Noris M.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2619","authenticated-orcid":false,"given":"Jaime E.","family":"Charris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"key":"7266_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0377-1237(06)80162-0","volume":"62","author":"V Agrawal","year":"2006","unstructured":"Agrawal V, Singh Z (2006) Miltefosine: first oral drug for treatment of visceral leishmaniasis. Med J Armed Forces India 62:66\u201367","journal-title":"Med J Armed Forces India"},{"key":"7266_CR2","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1128\/AAC.43.12.2910","volume":"43","author":"H Al-Abdely","year":"1999","unstructured":"Al-Abdely H, Graybill J, Loebenberg D, Melby P (1999) Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 43:2910\u20132914","journal-title":"Antimicrob Agents Chemother"},{"key":"7266_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijpddr.2014.02.002","volume":"4","author":"K Andrews","year":"2014","unstructured":"Andrews K, Fisher G, Skinner-Adams T (2014) Drug repurposing and human parasitic protozoan diseases. Int J Pasitol Drugs Drug Res 4:95\u2013111","journal-title":"Int J Pasitol Drugs Drug Res"},{"key":"7266_CR4","doi-asserted-by":"publisher","first-page":"7636","DOI":"10.1021\/acs.jmedchem.7b00143","volume":"60","author":"C Ang","year":"2017","unstructured":"Ang C, Jarrad A, Cooper M, Blaskovich M (2017) Nitroimidazoles: molecular fireworks that combat a broad spectrum of infectious diseases. J Med Chem 60:7636\u20137657","journal-title":"J Med Chem"},{"key":"7266_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejmech.2013.12.030","volume":"74","author":"Y Baquedano","year":"2014","unstructured":"Baquedano Y, Moreno E, Espuelas S, Nguewa P, Font M, Gutierrez K, Jim\u00e9nez-Ruiz A, Palop J, Sanmart\u00edn C (2014) Novel hybrid selenosulfonamides as potent antileishmanial agents. Eur J Med Chem 74:116\u2013123","journal-title":"Eur J Med Chem"},{"key":"7266_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.7705\/biomedica.v26i1.1511","volume":"26","author":"S Brito","year":"2006","unstructured":"Brito S, Crescente O, Fern\u00e1ndez A, Coronado A, Rodr\u00edguez N (2006) Eficacia de un \u00e1cido kaur\u00e9nico extra\u00eddo de la planta venezolana Wedelia trilobata (Aster\u00e1cea) contra Leishmania (V) braziliensis. Biomedica 26:180\u2013187","journal-title":"Biomedica"},{"key":"7266_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1039\/c4md00011k","volume":"5","author":"J Burrows","year":"2014","unstructured":"Burrows J, Elliott R, Kaneko T, Mowbrayd C, Watersona D (2014) The role of modern drug discovery in the fight against neglected and tropical diseases. MedChemComm 5:688\u2013700","journal-title":"MedChemComm"},{"key":"7266_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-9292-1-1","volume":"1","author":"K Chang","year":"2002","unstructured":"Chang K, McGwire B (2002) Molecular determinants and regulation of Leishmania virulence. Kinetoplastid Biol Dis 1:1","journal-title":"Kinetoplastid Biol Dis"},{"key":"7266_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/1747519819890559","volume":"44","author":"C Colmenares","year":"2020","unstructured":"Colmenares C, Rodr\u00edguez M, Acosta M, Charris J (2020) Synthesis and antimalarial activity of (S)-methyl-(7-chloroquinolin-4-ylthio) acetamidoalquilate derivatives. J Chem Res 44:161\u2013166","journal-title":"J Chem Res"},{"key":"7266_CR10","unstructured":"Drugs for Neglected Diseases initiative (https:\/\/dndi.org\/press-releases\/2021\/ghit-fund-renews-support-dndi-drug-discovery-early-stage-development-leishmaniasis-chagas-disease\/). Successful screening collaboration leads to a new lead optimization project. Accessed 17\u201305\u20132021"},{"key":"7266_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4269\/ajtmh.2001.65.685","volume":"65","author":"R Dietze","year":"2001","unstructured":"Dietze R, Carvalho S, Valli L, Berman J, Brewer T, Milhous W, Sanchez J, Schuster B, Grogl M (2001) Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 65:685\u2013689","journal-title":"Am J Trop Med Hyg"},{"key":"7266_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ejmech.2014.10.040","volume":"89","author":"V G\u00f3mez-P\u00e9rez","year":"2015","unstructured":"G\u00f3mez-P\u00e9rez V, Manzano J, Garc\u00eda-Hern\u00e1ndez R, Castanys S, Gamarro F, Campos J (2015) Design, synthesis and anti-leishmanial activity of novel symmetrical bispyridinium cyclophanes. Eur J Med Chem 89:362\u2013369","journal-title":"Eur J Med Chem"},{"key":"7266_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0001-706X(93)90083-N","volume":"55","author":"W Huber","year":"1993","unstructured":"Huber W, Koella J (1993) A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop 55:257\u2013261","journal-title":"Acta Trop"},{"key":"7266_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1051\/parasite\/2011182115","volume":"18","author":"P Loiseau","year":"2011","unstructured":"Loiseau P, Cojean S, Schr\u00e9vel J (2011) Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Parasite 18:115\u2013119","journal-title":"Parasite"},{"key":"7266_CR15","first-page":"675","volume-title":"Biotransformations leading to toxic metabolites: chemical aspect The Practice of Medicinal Chemistry","author":"A Macherey","year":"2015","unstructured":"Macherey A, Dansette P (2015) Biotransformations leading to toxic metabolites: chemical aspect The Practice of Medicinal Chemistry. Academic Press, New York, pp 675\u2013696"},{"key":"7266_CR16","first-page":"1398","volume":"60","author":"B Monge-Maillo","year":"2015","unstructured":"Monge-Maillo B, L\u00f3pez-V\u00e9lez R (2015) Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clin Infect Dis 60:1398\u20131404","journal-title":"Clin Infect Dis"},{"key":"7266_CR17","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1021\/acs.jmedchem.8b00147","volume":"62","author":"K Nepali","year":"2019","unstructured":"Nepali K, Lee H-Y, Liou J-P (2019) Nitro-Group-Containing Drugs. J Med Chem 62:2851\u20132893","journal-title":"J Med Chem"},{"key":"7266_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejmech.2017.09.064","volume":"141","author":"E Otero","year":"2017","unstructured":"Otero E, Garc\u00eda E, Palacios G, Yepes L, Carda M, Agut R, V\u00e9lez I, Cardona W, Robledo S (2017) Triclosan-caffeic acid hybrids: synthesis, leishmanicidal, trypanocidal and cytotoxic activities. Eur J Med Chem 141:73\u201383","journal-title":"Eur J Med Chem"},{"key":"7266_CR19","doi-asserted-by":"publisher","first-page":"e09744","DOI":"10.7554\/eLife.09744","volume":"5","author":"S Patterson","year":"2016","unstructured":"Patterson S, Wyllie S, Norval S, Stojanovski L, Simeons F, Auer J, Osuna-Cabello M, Read K, Fairlamb A (2016) The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. eLife 5:e09744","journal-title":"eLife"},{"key":"7266_CR20","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1007\/s10637-011-9716-3","volume":"30","author":"J Rodrigues","year":"2012","unstructured":"Rodrigues J, Charris J, Ferrer R, Gamboa N, \u00c1ngel J, Nitzche B, Hoepfner M, Lein M, Jung K, Abamjuk C (2012) Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo. Invest New Drugs 30:1426\u20131433","journal-title":"Invest New Drugs"},{"key":"7266_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0035-9203(02)90060-X","volume":"96","author":"N Rodr\u00edguez","year":"2002","unstructured":"Rodr\u00edguez N, De Lima H, Aguilar CM, Rodr\u00edguez A, Barker DC, Convit J (2002) Molecular epidemiology of cutaneous leishmaniasis in Venezuela. Trans R Soc Trop Med Hyg 96:105\u2013109","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"7266_CR22","doi-asserted-by":"publisher","first-page":"e2000002","DOI":"10.1002\/ardp.202000002","volume":"353","author":"M Rodr\u00edguez","year":"2020","unstructured":"Rodr\u00edguez M, Guti\u00e9rrez J, Dom\u00ednguez J, Peixoto P, Fern\u00e1ndez A, Rodr\u00edguez N, Deffieux D, Rojas L, Quideau S, Pouys\u00e9gu L, Charris J (2020) Synthesis and leishmanicidal evaluation of sulfanyl- andsulfonyl-tethered functionalized benzoate derivatives featuring a nitroimidazole moiety. Arch Pharm Chem Life Sci 353:e2000002","journal-title":"Arch Pharm Chem Life Sci"},{"key":"7266_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bioorg.2018.10.028","volume":"83","author":"A Romero","year":"2019","unstructured":"Romero A, Rodr\u00edguez N, Oviedo H (2019) Optimization of phthalazin-based aryl\/heteroarylhydrazones to design new promising antileishmanicidal agents: synthesis and biological evaluation of 3-aryl-6-piperazin-1,2,4-triazolo[3,4-a]phthalazines. Bioorg Chem 83:145\u2013153","journal-title":"Bioorg Chem"},{"key":"7266_CR24","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.1016\/j.bmcl.2012.06.083","volume":"22","author":"A Salahuddin","year":"2012","unstructured":"Salahuddin A, Agarwal S, Avecilla F, Azam A (2012) Metronidazole thiosalicylate conjugates: synthesis, crystal structure, docking studies and antiamoebic activity. Bioorg Med Chem Let 22:5694\u20135699","journal-title":"Bioorg Med Chem Let"},{"key":"7266_CR25","doi-asserted-by":"publisher","first-page":"32376","DOI":"10.1039\/C5RA02669E","volume":"5","author":"J Sangshetti","year":"2015","unstructured":"Sangshetti J, Kalam F, Kulkarni A, Rohidas A, Patilc R (2015) Antileishmanial drug discovery: comprehensive review of the last 10 years. RSC Adv 5:32376\u201332415","journal-title":"RSC Adv"},{"key":"7266_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1046\/j.1365-4362.2003.01955.x","volume":"42","author":"J Seeberger","year":"2003","unstructured":"Seeberger J, Daoud S, Pammer J (2003) Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol 42:576\u2013579","journal-title":"Int J Dermatol"},{"key":"7266_CR27","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1016\/j.ejmech.2010.04.033","volume":"45","author":"S Singh","year":"2010","unstructured":"Singh S, Jain A, Kaur S, Singh R, Kumar P, Garg S, Sharma S, Arora S (2010) Synthesis and antileishmanial activity of piperoyl-amino acid conjugates. Eur J Med Chem 45:3439\u20133445","journal-title":"Eur J Med Chem"},{"key":"7266_CR28","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2174\/1389200217666160819161444","volume":"17","author":"K Singh","year":"2016","unstructured":"Singh K, Garg G, Ali V (2016) Current therapeutics, their problems and thiol metabolism as potential drug targets in Leishmaniasis. Curr Drug Metab 17:897\u2013919","journal-title":"Curr Drug Metab"},{"key":"7266_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/09546634.2018.1472738","volume":"30","author":"V Somaratne","year":"2019","unstructured":"Somaratne V, Ranawaka R, Jayaruwan H, Wipuladasa D, de Silva S (2019) Randomized, double-blind study on intralesional metronidazole versus intralesional sodium stibogluconate in Leishmania donovani cutaneous leishmaniasis. J Dermatol Treat 30:87\u201391","journal-title":"J Dermatol Treat"},{"key":"7266_CR30","doi-asserted-by":"publisher","first-page":"E57","DOI":"10.1086\/322689","volume":"33","author":"J Soto","year":"2001","unstructured":"Soto J, Toledo J, Gutierrez P, Nicholls R, Padilla J, Engel J, Fischer C, Voss A, Berman J (2001) Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33:E57\u2013E61","journal-title":"Clin Infect Dis"},{"key":"7266_CR31","doi-asserted-by":"publisher","first-page":"7112","DOI":"10.1128\/AAC.03340-14","volume":"58","author":"T Stefanello","year":"2014","unstructured":"Stefanello T, Panice M, Ueda-Nakamura T, Sarragiotto M, Auz\u00e9ly-Velty R, Nakamura C (2014) N-butyl-[1-(4-methoxy)phenyl-9H-\u03b2-carboline]-3-carboxamide prevents cytokinesis in Leishmania amazonensis. Antimicrob Agents Chemother 58:7112\u20137120","journal-title":"Antimicrob Agents Chemother"},{"key":"7266_CR32","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/jac\/dkz172","volume":"74","author":"E Texaira","year":"2019","unstructured":"Texaira E, Rabello A, Aguiar M (2019) In vitro activity and in vivo efficacy of fexinidazole against new world Leishmania species. J Antimicrob Chemother 74:2318\u20132325","journal-title":"J Antimicrob Chemother"},{"key":"7266_CR33","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1021\/acs.jmedchem.5b01699","volume":"59","author":"A Thompson","year":"2016","unstructured":"Thompson A, O\u2019Connor P, Blaser A, Yardley V, Maes L, Gupta S, Launay D, Martin D, Franzblau S, Wan B, Wang Y, Ma Z, Denny W (2016) Repositioning antitubercular 6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for neglected tropical diseases: structure\u2212activity studies on a preclinical candidate for visceral leishmaniasis. J Med Chem 59:2530\u20132550","journal-title":"J Med Chem"},{"key":"7266_CR34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.bmcl.2014.09.078","volume":"25","author":"A Tiwari","year":"2015","unstructured":"Tiwari A, Kumar S, Shivahare R, Kant P, Gupta S, Suryawanshi S (2015) Chemotherapy of leishmaniasis part XIII: design and synthesis of novel heteroretinoid-bisbenzylidine ketone hybrids as antileishmanial agents. Bioorg Med Chem Lett 25:410\u2013413","journal-title":"Bioorg Med Chem Lett"},{"key":"7266_CR35","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.1021\/acs.jmedchem.9b00628","volume":"62","author":"A Upadhyay","year":"2019","unstructured":"Upadhyay A, Chandrakar P, Gupta S, Parmar N, Kumar Singh S, Rashid M, Kushwaha P, Wahajuddin M, Sashidhara K, Kar S (2019) Synthesis, biological evaluation, structure-activity relationship, and mechanism of action studies of quinoline\u2212metronidazole derivatives against experimental visceral leishmaniasis. J Med Chem 62:5655\u20135671","journal-title":"J Med Chem"},{"key":"7266_CR36","unstructured":"World Health Organization. Leishmaniases: epidemiological report of the Americas N\u00b0 7 \u2013 March 2019. WHO\/PAHO Department of Neglected Infectious Diseases https:\/\/www.who.int\/leishmaniasis\/resources\/who_paho_era7\/en\/. Accessed 02\u201307\u20132020"},{"key":"7266_CR37","doi-asserted-by":"publisher","first-page":"119re1","DOI":"10.1126\/scitranslmed.3003326","volume":"4","author":"S Wyllie","year":"2012","unstructured":"Wyllie S, Patterson S, Stojanovski L, Simeons F, Norval S, Kime R, Read K, Fairlamb A (2012) The antitrypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med 4:119re1","journal-title":"Sci Transl Med"},{"key":"7266_CR38","doi-asserted-by":"publisher","first-page":"e1005971","DOI":"10.1371\/journal.ppat.1005971","volume":"12","author":"S Wyllie","year":"2016","unstructured":"Wyllie S, Roberts A, Norval S, Patterson S, Foth B, Berriman M, Read K, Fairlamb A (2016) Activation of bicyclic nitro-drugs by a novel nitroreductase (ntr2) in leishmania. PLoS Pathog 12:e1005971","journal-title":"PLoS Pathog"},{"key":"7266_CR39","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/jac\/43.6.793","volume":"43","author":"L Zhai","year":"1999","unstructured":"Zhai L, Chen M, Blom J, Theander T, Christensen S, Kharazmi A (1999) The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother 43:793\u2013803","journal-title":"J Antimicrob Chemother"}],"container-title":["Parasitology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-021-07266-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00436-021-07266-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-021-07266-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T04:10:00Z","timestamp":1630037400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00436-021-07266-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["7266"],"URL":"https:\/\/doi.org\/10.1007\/s00436-021-07266-w","relation":{},"ISSN":["0932-0113","1432-1955"],"issn-type":[{"type":"print","value":"0932-0113"},{"type":"electronic","value":"1432-1955"}],"subject":[],"published":{"date-parts":[[2021,8,9]]},"assertion":[{"value":"12 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}